Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR)

NCT02921139 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma(HCC)

Interventions

RADIATION: Stereotactic ablative radiotherapy (SABR)
PROCEDURE: Re-Transcatheter arterial chemoembolization (re-TACE)

Sponsor

Dalin Tzu Chi General Hospital

Collaborators

[object Object]
[object Object]